Fulltext

Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort

Obón-Santacana M 1 , Freisling H 2 , Peeters PH 3 , Lujan-Barroso L 1 , Ferrari P 2 , Boutron-Ruault MC 4 Show all authors , Mesrine S 4 , Baglietto L 5 , Turzanski-Fortner R 6 , Katzke VA 6 , Boeing H 7 , Quirós JR 8 , Molina-Portillo E 9 , Larrañaga N 10 , Chirlaque MD 10 , Barricarte A 10 , Khaw KT 11 , Wareham N 12 , Travis RC 12 , Merritt MA 13 , Gunter MJ 13 , Trichopoulou A 14 , Lagiou P 14 , Naska A 14 , Palli D 15 , Sieri S 16 , Tumino R 17 , Fiano V 18 , Galassom R 19 , Bueno-de-Mesquita HB 13 , Onland-Moret NC 20 , Idahl A 21 , Lundin E 22 , Weiderpass E 23 , Vesper H 24 , Riboli E 13 , Duell EJ 1

Affiliations 

  • 1 Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
  • 2 Dietary Exposure Assessment Group, International Agency for Research on Cancer, Lyon, France
  • 3 Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
  • 4 Inserm, CESP Centre for Research in Epidemiology and Population Health, Lifestyle, Genes and Health: Integrative Trans-Generational Epidemiology, Villejuif, France
  • 5 Cancer Council of Victoria, Cancer Epidemiology Centre, Melbourne, Australia
  • 6 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 7 Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany
  • 8 Public Health Directorate, Asturias, Spain
  • 9 Escuela Andaluza De Salud Pública, Instituto De Investigación Biosanitaria Ibs, GRANADA, Hospitales Universitarios De Granada/Universidad De Granada, Granada, Spain
  • 10 CIBER, Epidemiology and Public Health CIBERESP, Madrid, Spain
  • 11 University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
  • 12 Nuffield Department of Population Health University of Oxford, Cancer Epidemiology Unit, Oxford, United Kingdom
  • 13 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
  • 14 Hellenic Health Foundation, Athens, Greece
  • 15 Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy
  • 16 Epidemiology and Prevention Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
  • 17 Cancer Registry and Histopathology Unit, "Civic - M.P.Arezzo" Hospital, ASP Ragusa, Italy
  • 18 Department of Medical Sciences University of Turin, Unit of Cancer Epidemiology-CERMS, Turin, Italy
  • 19 Biostatistics and Cancer Registry, IRCCS Centro Di Riferimento Oncologico Di Basilicata, Unit of Clinical Epidemiology, Rionero in Vulture, Potenza, Italy
  • 20 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
  • 21 Department of Clinical Sciences, Obstetrics and Gynecology, Nutritional Research Umeå University, Umeå, Sweden
  • 22 Department of Medical Biosciences, Pathology Umeå University, Umeå, Sweden
  • 23 Department of Community Medicine, Faculty of Health Sciences, the Arctic University of Norway, University of Tromsø, Tromsø, Norway
  • 24 Centers for Disease Control and Prevention, Atlanta, GA
Int J Cancer, 2016 Mar 01;138(5):1129-38.
PMID: 26376083 DOI: 10.1002/ijc.29853

Abstract

Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1 : 0.84, 95%CI: 0.49-1.48; HRHbGA;Q5vsQ1 : 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications